Alexion Pharmaceuticals (NASDAQ:ALXN) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32, Briefing.com reports. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the firm posted $2.02 EPS. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. Alexion Pharmaceuticals updated its FY 2019 guidance to $10.25-10.40 EPS and its FY19 guidance to $10.25-10.40 EPS.
Shares of NASDAQ:ALXN traded down $1.97 during midday trading on Thursday, reaching $104.66. 969,958 shares of the company’s stock were exchanged, compared to its average volume of 1,689,730. The firm’s 50 day simple moving average is $101.73 and its two-hundred day simple moving average is $117.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The stock has a market cap of $22.26 billion, a price-to-earnings ratio of 14.76, a P/E/G ratio of 0.97 and a beta of 1.67. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.86.
ALXN has been the topic of several analyst reports. Raymond James set a $168.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Citigroup set a $150.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Bank of America initiated coverage on Alexion Pharmaceuticals in a report on Thursday, October 17th. They set a “buy” rating on the stock. Piper Jaffray Companies set a $180.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 6th. Finally, Morgan Stanley reduced their price target on Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $159.76.
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.